## AMT: American Tower Corporation (REI - XLRE: Real Estate

### Executive Summary

No thesis match: MRS_20 -1.2% below STRENGTH zone (4.0-10.0%); PEG 52.79 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($174.17)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. London & Capital Asset Management Ltd Lowers Stock Holdings in American Tower Corporation $AMT**
- Source: MarketBeat | 20251209T130745 | Neutral | Relevance: 98%
-  London & Capital Asset Management Ltd significantly decreased its stake in American Tower Corporation (NYSE:AMT) by 60.8% in the second quarter, valuing its remaining 27,922 shares at $6.17 million. Despite this, other institutional investors like Blossom Wealth Management, TFG Advisers LLC, Novem Group, Analyst IMS Investment Management Services Ltd., and Marion Wealth Management increased their holdings in American Tower. The company recently reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $1.70 per share, yielding 3.7%.

**2. American Tower stock price target maintained at $260 by UBS on growth outlook**
- Source: Investing.com | 20251210T160544 | Bullish | Relevance: 98%
-  UBS has reiterated its Buy rating and $260.00 price target for American Tower (NYSE:AMT) following a presentation by its President and CEO Steve Vondran. The company outlined 2026 priorities including maximizing organic growth, driving efficiencies by lowering SG&A, and focusing capital allocation on developed markets to deliver industry-leading AFFO per share growth. Additionally, the company is dealing with ongoing Echostar litigation, has completed an $850 million senior unsecured notes offering, and is preparing for the retirement of its Chief Accounting Officer.

**3. Fayez Sarofim & Co Purchases 17,961 Shares of American Tower Corporation $AMT**
- Source: MarketBeat | 20251209T110818 | Somewhat-Bullish | Relevance: 98%
-  Fayez Sarofim & Co significantly increased its stake in American Tower Corporation (NYSE:AMT) by 52.8%, purchasing 17,961 additional shares, bringing their total holdings to 51,992 shares valued at approximately $11.49 million. This comes as American Tower reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $1.70 per share. Several other institutional investors have also adjusted their positions in American Tower, with 92.69% of the stock owned by institutional investors.

**4. American Tower Corporation $AMT Stock Holdings Trimmed by State Street Corp**
- Source: MarketBeat | 20251209T131405 | Neutral | Relevance: 98%
-  State Street Corp reduced its stake in American Tower Corporation (NYSE:AMT) by 0.6% in the second quarter, ending with 21,113,680 shares valued at approximately $4.70 billion. Despite this, insider Eugene F. Reilly increased his holdings by purchasing 5,554 shares, and the company reported strong quarterly earnings, beating estimates with EPS of $2.78 and revenue of $2.72 billion. American Tower also declared a $1.70 quarterly dividend.

**5. Blue Door Asset Management LLC Invests $3.27 Million in American Tower Corporation $AMT**
- Source: MarketBeat | 20251211T085133 | Somewhat-Bullish | Relevance: 98%
-  Blue Door Asset Management LLC purchased 14,800 shares of American Tower Corporation (NYSE:AMT) valued at approximately $3.27 million during the second quarter, making it their 14th largest position. Other institutional investors have also adjusted their holdings in American Tower. Meanwhile, a director recently bought over 5,500 shares, and several analysts have issued "Buy" or "Overweight" ratings with price targets ranging from $200 to $250.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 3)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Morgan Stanley | $225 | $235 | -4% |
| 2025-12-01 | Barclays | $200 | $203 | -1% |
| 2025-11-17 | Barclays | $203 | $251 | -19% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Morgan Stanley | main | Overweight |
| 2025-12-01 | Barclays | down | Equal-Weight |
| 2025-11-17 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.99M) |
| Sells | 2 ($0.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 13.6% (+1.0%)
- Blackrock Inc.: 9.7% (-0.6%)
- JPMORGAN CHASE & CO: 6.6% (+142.8%)
- State Street Corpora: 4.5% (-0.9%)
- Cohen & Steers Inc.: 2.9% (-2.9%)

### Key Risks

1. Valuation stretched: PEG 52.8x requires aggressive growth execution.
2. Long-term trend broken: trading 11.2% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 52.79 signals overvaluation risk, limited margin of safety. Forward P/E 26.0x attractive for 37% earnings growth. Quality metrics strong (ROE 29%, margin 28%). Analyst sentiment negative (3 target cuts vs 0 raises). Insider buying signal ($1.0M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $85.1B |
| Beta | 0.92 |
| 52W Range | $172.51 - $234.33 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 52.79 |
| Forward P/E | 26.0 |
| Current P/E | 35.6 |
| YoY Growth | 36.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -2.9% to -1.2% (+1.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.5%) - potential reversal signal. Below SMA200 (0.89x), long-term trend not supportive. MACD histogram positive (0.60), confirming momentum. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.19% (CS: 37) | Neutral |
| RSI_14 | 51.6 | Neutral |
| MACD Histogram | 0.60 | Bullish |
| vs SMA20 | 1.010x | Above |
| vs SMA50 | 0.992x | Below |
| vs SMA200 | 0.888x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $181.71
- **Stop Loss:** $174.17 (4.1% risk)
- **Target:** $189.25 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 183
- **Position Value:** $33,252.93
- **Portfolio %:** 33.25%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-24 (Est: $1.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.65 | $1.82 | +10.1% |
| 2025Q2 | $1.66 | $0.78 | -53.0% |
| 2025Q1 | $1.57 | $1.04 | -33.7% |
| 2024Q4 | $1.98 | $2.62 | +32.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*